KDNY Company Profile and Key Details
Chinook Therapeutics, Inc.
KDNY Stock Price Chart
Stock Price Today
Chinook Therapeutics, Inc. (KDNY) stock surged +0.22%, trading at $40.39 on NASDAQ, up from the previous close of $40.30. The stock opened at $40.31, fluctuating between $40.30 and $40.51 in the recent session.
Stock Snapshot
Stock Price History Chart
Contact Details
About Company
Chinook Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases. The company's lead clinical program is atrasentan, a Phase III endothelin receptor antagonist for the treatment of IgA nephropathy and other proteinuric glomerular diseases. Its product candidates also include BION-1301, an anti-APRIL monoclonal antibody is being evaluated in a Phase I/II trial for IgA nephropathy; and CHK-336, an oral small molecule LDHA inhibitor for the treatment of primary hyperoxaluria, as well as research programs for other rare and severe chronic kidney diseases. Chinook Therapeutics, Inc. is headquartered in Seattle, Washington.
Company Information
| Employees | 214 |
| Beta | 0.67 |
| Sales or Revenue | $6.13M |
| 5Y Sales Change% | 402% |
| Fiscal Year Ends | December |
| Sector | Healthcare |
| Industry | Biotechnology |
Frequently Asked Questions
Chinook Therapeutics, Inc. (NASDAQ: KDNY) stock price is $40.39 in the last trading session. During the trading session, KDNY stock reached the peak price of $40.51 while $40.30 was the lowest point it dropped to. The percentage change in KDNY stock occurred in the recent session was 0.22% while the dollar amount for the price change in KDNY stock was $0.09.
The NASDAQ listed KDNY is part of Biotechnology industry that operates in the broader Healthcare sector. Chinook Therapeutics, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.
Dr. Alan Glicklich M.D.
Executive Officer
Ms. Noopur Batsha Liffick
Vice President of Investor Relations & Corporation Communications
Ms. Delphine Imbert Ph.D.
Senior Vice President of CMC & Technical Operations
Mr. Kirk D. Schumacher J.D.
Senior Vice President & Gen. Counsel
Ms. Jodi Jamieson
Vice President of HR
Dr. Charlotte Jones-Burton M.D., M.S.
Senior Vice President of Product Devel. & Strategy
Mr. Eric L. Dobmeier J.D.
Pres, Chief Executive Officer & Director
Mr. Tom Frohlich
Chief Operating Officer
Mr. Andrew James King D.V.M., Ph.D.
Chief Scientific Officer
Mr. Eric H. Bjerkholt M.B.A.
Chief Financial Officer
Ms. Sukhi Thethy
Senior Vice President of Fin. & Accounting
KDNY's closing price is 120.23% higher than its 52-week low of $18.34 where as its distance from 52-week high of $40.51 is -0.3%.
Number of KDNY employees currently stands at 214.
Official Website of KDNY is: https://www.chinooktx.com
KDNY could be contacted at phone 206 485 7241 and can also be accessed through its website. KDNY operates from 400 Fairview Avenue North, Seattle, WA 98109, United States.
KDNY stock volume for the day was 3.28M shares. The average number of KDNY shares traded daily for last 3 months was 2.04M.
The market value of KDNY currently stands at $2.71B with its latest stock price at $40.39 and 67.05M of its shares outstanding.
Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.
© 2025 Stocks Telegraph All rights reserved.
Most stock quote data provided by financialmodelingprep.com